Connect with us

International

Horos Asset Management 4Q20 Commentary

Horos Asset Management commentary for the fourth quarter ended December 31, 2020 discussing an approach to the Austrian Business Cycle Theory. Q4 2020 hedge fund letters, conferences and more Dear co-investor, Finally, a very difficult year for everyone..

Published

on

Austrian Business Cycle Theory wellshire financial services 60/40 Portfolio Allocation

Horos Asset Management commentary for the fourth quarter ended December 31, 2020 discussing an approach to the Austrian Business Cycle Theory.

Get The Full Ray Dalio Series in PDF

Get the entire 10-part series on Ray Dalio in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues

Q4 2020 hedge fund letters, conferences and more

Dear co-investor,

Finally, a very difficult year for everyone has come to an end. I can add little to the encouragement and gratitude for your trust that we have shown you in our previous letters. May the arrival of the vaccine be the turning point we all wish for our lives.

Indeed, that turning point seems to have already come to the financial markets, with equity indexes experiencing a strong recovery in the last months of the year. This time it was the most cyclical and smaller, less liquid companies that outperformed. Thus, Horos Value Internacional returned 26.3% in the quarter, compared to 11.9% in its benchmark index. On the other hand, Horos Value Iberia posted a return of 27.9%, outperforming the 22.8% rise of its benchmark.

However, we continue to believe that the companies we own in our portfolio, mostly cyclical and smaller companies, have a high upside potential. As you know, our exposure to the commodities sector is a significant feature of our funds. It is therefore very important that you understand how we analyze this industry and select the companies in which we invest. This is what we will be devoting the bulk of this last letter of 2020 to, including an account of our investment mistake in offshore drilling companies. As we always say, in order to improve our investment process, we must detect the mistakes we make and learn what decisions/reasons led us to make them, in order to reduce the chances of these situations occurring again.

My best wishes for 2021.

Yours sincerely,

Javier Ruiz, CFA

Chief Investment Officer

Horos Asset Management

Executive summary

Cycles will never stop occurring. - Howard Marks

The arrival of the COVID-19 vaccines may be marking a turning point in our lives and in financial markets, which have already begun to price in an expected economic recovery. In this new environment of less uncertainty, the stock performance of the hardest-hit sectors and investment themes over the last two and a half years has been outstanding. These are companies with more cyclical businesses and those with a smaller size and liquidity. Our funds have not been immune to this recovery, as they have strong exposure to these companies, which have been so badly affected by the dynamics we have mentioned in previous letters. However, we still see a very high upside potential in our portfolios, where we can highlight our exposure to the commodities sector. For this reason, we dedicate the current letter to explain our analysis of this industry, through tools such as the capital cycle analysis or the Austrian Business Cycle Theory, as well as to comment on some of our historical and current holdings in this area, so loved and hated by the investment community.

Additionally, we will discuss the most significant changes to our portfolios. Among others, we can highlight that in Horos Value Internacional we exited our position in Qiwi, after the regulatory uncertainty in its business increased, as well as KKR, due to its good performance. On the other hand, we initiated two new positions in the quarter. Specifically, we invested in the podcast hosting company Liberated Syndication, as well as in GAMCO Investors, the historic asset manager with an excellent track record in value investing. In Horos Value Iberia, we sold Sonae Capital, following the improvement of the takeover bid launched by the Azevedo family, and added Ence, after the announcement of the sale of 49% of its energy division, unveiling significant value in the company, while at the same time reducing its debt.

The history that always repeats itself

Look back over the past with its changing empires that rose and fell, and you can foresee the future too. - Marco Aurelio

The team that Alejandro, Miguel and I form, have had—as the co-investors who have been with us a long time know—a generalist profile when it comes to approaching investment. By this I mean our willingness to invest in any sector or geography, as long as the company meets the requirements we require to be added to our funds. Thus, throughout our professional career, our portfolios have included stocks belonging to sectors as diverse as technology, real estate, finance, retail and commodities, as far away as Japan (when nobody wanted to know anything about its stock market, back in 2012), the United States, Hong Kong, Russia and even Colombia.

In order to be able to cover this vast investment universe, it is vital to have tools or mental models that help us understand how markets work and identify potentially exploitable inefficiencies. In the first quarter of 2020 (see here), we talked about the most relevant mental models that the Horos team uses. In particular, we relied on complex adaptive systems to understand the mechanisms behind the market excesses, as well as the sharp market decline (and subsequent recovery), as a result of the uncertainty associated with the Covid-19 pandemic and its impact on the world's economies. On this occasion, I would like to delve into another mental model, which is essential to our work and will help you understand our significant exposure to the commodities sector of the last few years: the capital cycle analysis.

The capital cycle analysis is the conceptual framework that can serve as a guide in our study of industries with businesses and products, in general, little differentiated and therefore more likely to suffer major cycles. Hence, it is a very useful tool for investing in commodity-related companies. This analysis, popularized in recent years by Marathon Asset Management in the wonderful (the best?) investment book Capital Returns, focuses particularly on the study of the supply behavior of each sector, as this is the predominant force in the different phases of the capital cycle.1

Capital cycle analysis, however, focuses on supply rather than demand. Supply prospects are far less uncertain than demand, and thus easier to forecast.2

To better understand this, let's look at the four phases that make up these capital cycles in the commodities sector:

  • Boom: the market environment is positive for the industry's producers (supply), as there is an unsatisfied demand in the market, which causes a rise in the commodity prices and a return on the invested capital of the producers that is higher than its cost. The boom phase usually coincides with significant stock market gains of the companies in the sector.
  • Investor optimism: the prospect of large returns attracts new capital, increasing the current supply, by exploiting areas with higher extraction costs (in the case of mining, for example, producing the lower grade deposits, now profitable), and increasing the future supply, by developing new projects that will come into production years later. The industry's discipline is lost. In this phase, companies usually trade at very demanding valuations, discounting all the good and very little of the bad to come.
  • Depression: optimism and lack of discipline lead to an excess of supply (and competition), usually exacerbated by demand that is weaker than initially expected. This imbalance triggers a collapse in commodity prices and returns on capital fall below its cost. The depressed phase is accompanied by sharp declines in the stock market value of companies in the sector, as it cannot be otherwise.
  • Investor pessimism: low returns lead to a drastic reduction in investment in current supply (closure of less efficient deposits/mines) and future supply (no money whatsoever allocated to the exploration and development of new projects), as well as sector consolidation. Unlike in the phase of investor optimism, in this stage the companies trade at depressed valuations, discounting all the bad (permanently low commodity price scenarios, with consequently value-destroying capital returns) and none of the good (capital discipline sows the seed of future recovery). The lack of supply-side investment tends to drag on to the point of triggering an imbalance that supports supply, starting the cycle with its boom phase again.

Therefore, we clearly see the power of supply in the formation of these cycles and how vital it is to know what phase the sector is in, to try to take advantage of the periods of investor pessimism and boom in the cycle.

Note, additionally, the relevance of other mental models that can help us to complement the above analysis, belonging to the field of behavioral economics. Overconfidence (especially when forecasting prices or project development times), optimism (fueling the overconfidence just mentioned), anchoring bias (extrapolating the current market situation into the future, without analyzing the expected supply and demand dynamics), cognitive dissonance leading to the rationalization of irrational beliefs (prices will not fall) in the face of contrary evidence (increased competition and excess supply in the future) or inside view (thinking, for example, that my mining project will see the light of day in 5 years, when the history of other projects in the industry says that the average time is 8 years), among many others, can help us understand and anticipate the irrationality that most company executives in these sectors, as well as investors, continually incur in injecting capital at the worst times—when everything is going well and can only get worse—and draining it at the best times—when everything is going badly and can only get better.3

High profitability loosens capital discipline in an industry. When returns are high, companies are inclined to boost capital spending.4

However, although the capital cycle analysis that we have described, supported by behavioral economics, is very helpful in navigating with certain guarantees of success the ups and downs of cyclical industries, we have another—more global—theoretical framework for understanding the formation of capital cycles, both at the industry and macro level: the

Austrian Business Cycle Theory.

An approach to the Austrian Business Cycle Theory

There is nothing more practical than a good theory. - Jesús Huerta de Soto

I am aware that this section may be difficult for the reader to follow, although I have tried to simplify the underlying idea as much as possible. If you prefer, you can jump to the next section, "The commodity supercycle", where we apply the theory exposed here.

The Austrian Business Cycle Theory (“ABCT", from now on) is possibly one of the most interesting models developed by the Austrian School of Economics. Some economists point to the scholastics of the School of Salamanca in the 16th century (Francisco de Vitoria, Martín de Azpilicueta, Diego de Covarrubias or Luis de Molina) as the origin or precursors of this school of economics.5 However, its foundation, as such, dates back to 1871, with the publication of Carl Menger's Principles of Political Economy. Later, during the last century, economists such as Ludwig von Mises, Friedrich von Hayek or Murray Rothbard, made the school more notorious. In Spain, we also have great scholars who belong to or are related to the Austrian School, two of whom stand: Jesús Huerta de Soto and Juan Ramón Rallo. Precisely, these two economists have written two essential books to better understand the ABCT: Money, Bank Credit, and Economic Cycles (by Jesús Huerta de Soto) and A Critique of Mises' Monetary Theory (by Juan Ramón Rallo).6

It is not the purpose of this letter to go into detail on the work (and differences) of these authors, nor to write twenty pages developing the ABCT. However, it is necessary to understand its essence in order to put it into practice in our subsequent analysis of the commodities sector. Basically, the Austrian Business Cycle Theory states that cycles are aggregate miscoordinations between the consumption plans of savers and the production plans of investors or entrepreneurs.7 Why do these miscoordinations occur? Because of the widespread liquidity degradation of economic agents, through the indiscriminate abuse of the maturity and risk mismatch. In other words, borrowing through short-term financing to invest in long-term maturity assets. This lack of coordination and liquidity degradation is magnified through the banking system, which acts as a financial intermediary facilitating this mismatch.

Why does the banking sector operate in this way? Basically, for three reasons. First, because it is very profitable to arbitrage the interest rate curve, taking on short-term debt (for example, by creating demand deposits or borrowing from other financial institutions) in order to invest in the long term (usually by granting loans to individuals and companies that mature in the distant future), due to the term spread that normally exists (the longer the term, the higher the interest rate) to compensate for the risks associated with longer maturities. Second, because, although banks take an excessive and unsustainable risk with this approach, they can always count on the lender (and buyer) of last resort: the central bank. Third, because the central bank itself, through its monetary policy, encourages banks to engage in this maturity mismatch.

An illustrative example of the maturity mismatch is the following:

To help understand the role of the bank as a financial intermediary (and oversimplifying), let's imagine that an average citizen, named Julian, wants to lend ten thousand euros to his brother-in-law so that he can buy some machinery he needs for his new business. His brother-in-law promises him that in two years he will pay him back those ten thousand euros, plus an additional four hundred euros as interest for the time spent and the risk incurred. If Julian had that money in savings, he could decide not to use it for two years and lend it to his brother-in-law, so there would be a temporal coordination between his savings/consumption plan and his investment plan (two years). However, Julian does not have that money available or prefers to spend it, so he turns to his mother to lend him those ten thousand euros, charging him two hundred euros in interest at the end of those two years. Julian lends this money to his brother-in-law and, if everything goes as expected, at the end of the second year he will have pocketed two hundred euros for his role as financial intermediary (ten thousand four hundred that his brother-in-law will return to him, minus ten thousand two hundred that he will give to his mother).

So far there is no maturity mismatch and the risk comes from his brother-in-law not paying back in due time and at the right conditions. Let's now imagine that Julian's mother tells him that she will lend him the money, but that she may need it in three months to buy a car. In that case, if Julian goes ahead with the financial transaction, he begins to take a clear liquidity (and solvency) risk because his mother may demand the money before he gets it back. If so, Julian will need someone to lend him ten thousand euros (plus interest) within three months, in order to be able to pay his mother back.

Well, this is exactly what banks do, but with much greater mismatch and liquidity risks, always taking for granted that they will be able to refinance their debt—thanks to the fact that, ultimately, they can be rescued by the central bank. This would mean that Julian could, as a last resort, always turn to his father if he could not get anyone to refinance him, to repay the debt to his mother if she needed the money before he could get back what he had lent to his brother-in-law.

This persistent mismatch carried out by the banking sector—and other very important economic agents, such as the so-called "shadow banking"—leads to the classic flattening of the yield curve, encouraging agents to take on more debt in order to develop longer-term and, therefore, more illiquid investment projects (let’s imagine that Julian's brother-in-law takes advantage of this decline in long-term rates to ask him for money for another, now more attractive, ten-year project) and consequently discouraging long-term savings. However, and this is the key, there has been no coordination between the plans of savers and those of entrepreneurs. Savers are providing short-term funds because they want to consume in the short term (remember Julian's mother and the car). Entrepreneurs (Julian's brother-in-law), however, find long-term financing through the banking system (Julian), as if such coordination did exist (ten-year business project). This lack of coordination can go on for some time, increasing the risks taken by the banking sector, making it more fragile and unstable as well as generating competition bidding up for the resources of economic agents, which often leads to inflation and, on occasion, asset bubbles.

How do we get to inflation? On the one hand, entrepreneurs are focused on new long-term plans that are further away from the end product (projects that take years to complete, such as developing new machinery, a capital good, for the more efficient manufacture of automobiles). On the other hand, savers, as we have mentioned, have short-term consumption plans (the purchase of the car is planned now). As they make these plans, the demand for the goods already produced or consumer goods rises, causing inflationary pressures, since not enough consumer goods are being manufactured to meet current demand (the entrepreneur is investing the credit in developing new machinery, not in speeding up automobile production). This inflationary pressure is further exacerbated as new projects compete with the rest of the agents bidding up for the same factors of production (labor, capital, raw materials). If there were temporal coordination between savings and investment, these factors of production would be allocated to projects demanded by the savers according to their time preferences, and this pressure would disappear.

Since this does not happen, all stages of production compete for the same resources, triggering inflationary processes of the first (e.g. wage and commodity price increases) and second order (wage increases allow more products to be demanded and, in addition, bottlenecks take place in commodity industries, given that supply cannot meet the growing demand, which causes commodity inflation). In addition, unless central banks try to prevent this, interest rates rise, as economic agents also compete for bank credit in order to carry out their consumption and investment plans.

Eventually, the mismatch between short-term savings (and funding) plans and long-term investment projects becomes unsustainable, as many of these projects prove to be unprofitable. A (desperate) phase of struggle for liquidity begins, as agents seek to refinance their debt so as not to be forced to abandon their business plans. However, financiers become more cautious in this environment and restrict the supply of credit, which puts upward pressure on interest rates, worsening the financial situation of businesses. In order to be able to repay part of the debt, businessmen proceed to abandon investment projects with poorer prospects, initiating a fall in the demand for factors of production (layoffs begin and the demand for commodities falls). However, the liquidity in the system is not enough to sustain the rest of the projects that businessmen were struggling to maintain, and the depression phase begins, which may be more or less pronounced. In this phase, companies go bust, its assets are liquidated and the demand for factors of production plummets, with prices falling across the board (deflation) along with interest rates (lower demand for credit).

It is at this point that the huge risk taken by the banks with the mismatching of maturities becomes apparent, as they find that their assets (loans) lose a large part of their value (the projects they back go bankrupt or generate less cash flow than expected). Moreover, since they operate with massive leverage, a small loss in their assets' value can wipe out all of the entity's equity. This is why most banks carry out large capital raises at the worst possible times, to help them avoid bankruptcy, and are forced—to a greater or lesser extent—to be bailed out by the central bank. This is one of the reasons why, historically, we have been averse to investing in the financial sector. The maturity mismatch, together with the massive leverage, makes the financial sector (especially the banking sector) a fragile and unsustainable business in the long term, with a few honorable exceptions in our portfolios, such as S&U, AerCap or Catalana Occidente, where prudent management of maturities and leverage makes them excellent businesses. I will leave, as a reflection, whether banks would take so much risk, which is so detrimental to the economy due to the lack of coordination and cycles they generate, if there were no such central bank as there is now.

Lastly, the depression phase forces a restructuring of the different stages of production in line with the savings/consumption plans of the economies. This is a painful process of recapitalization, although necessary for the economy to begin its recovery phase as soon as possible. Hence, most interventionist policies by central banks or governments contribute negatively to this recovery by distorting the behavior of economic agents and maintaining a situation of recession or stagnation over time.

In short, as we have just seen, the Austrian Business Cycle Theory helps us to have a more global view of what may be driving the supply and demand of commodities, as well as their prices, while the classic analysis of the capital cycle focuses exclusively on the industry's supply, failing to explain what underlies demand and price formation. This is especially true in synchronized commodity cycles, where prices move in unison and where the dynamics specific to each commodity lose much of their relevance. The latest commodity supercycle is a clear example of this phenomenon.

Read the full commentary here.

The post Horos Asset Management 4Q20 Commentary appeared first on ValueWalk.

Read More

Continue Reading

International

EyePoint poaches medical chief from Apellis; Sandoz CFO, longtime BioNTech exec to retire

Ramiro Ribeiro
After six years as head of clinical development at Apellis Pharmaceuticals, Ramiro Ribeiro is joining EyePoint Pharmaceuticals as CMO.
“The…

Published

on

Ramiro Ribeiro

After six years as head of clinical development at Apellis Pharmaceuticals, Ramiro Ribeiro is joining EyePoint Pharmaceuticals as CMO.

“The retinal community is relatively small, so everybody knows each other,” Ribeiro told Endpoints News in an interview. “As soon as I started to talk about EyePoint, I got really good feedback from KOLs and physicians on its scientific standards and quality of work.”

Ribeiro kicked off his career as a clinician in Brazil, earning a doctorate in stem cell therapy for retinal diseases. He previously held roles at Alcon and Ophthotech Corporation, now known as Astellas’ M&A prize Iveric Bio.

At Apellis, Ribeiro oversaw the Phase III development, filing and approval of Syfovre, the first drug for geographic atrophy secondary to age-related macular degeneration (AMD). The complement C3 inhibitor went on to make $275 million in 2023 despite reports of a rare side effect that only emerged after commercialization.

Now, Ribeiro is hoping to replicate that success with EyePoint’s lead candidate, EYP-1901 for wet AMD, which is set to enter the Phase III LUGANO trial in the second half of the year after passing a Phase II test in December.

Ribeiro told Endpoints he was optimistic about the company’s intraocular sustained-delivery tech, which he said could help address treatment burden and compliance issues seen with injectables. He also has plans to expand the EyePoint team.

“My goal is not just execution of the Phase III study — of course that’s a priority — but also looking at the pipeline and which different assets we can bring in to leverage the strength of the team that we have,” Ribeiro said.

Ayisha Sharma


Remco Steenbergen

Sandoz CFO Colin Bond will retire on June 30 and board member Remco Steenbergen will replace him. Steenbergen, who will step down from the board when he takes over on July 1, had a 20-year career with Philips and has held the group CFO post at Deutsche Lufthansa since January 2021. Bond joined Sandoz nearly two years ago and is the former finance chief at Evotec and Vifor Pharma. Investors didn’t react warmly to Wednesday’s news as shares fell by almost 4%.

The Swiss generics and biosimilars company, which finally split from Novartis in October 2023, has also nominated FogPharma CEO Mathai Mammen to the board of directors. The ex-R&D chief at J&J will be joined by two other new faces, Swisscom chairman Michael Rechsteiner and former Unilever CFO Graeme Pitkethly.

On Monday, Sandoz said it completed its $70 million purchase of Coherus BioSciencesLucentis biosimilar Cimerli sooner than expected. The FDA then approved its first two biosimilars of Amgen’s denosumab the next day, in a move that could whittle away at the pharma giant’s market share for Prolia and Xgeva.

Sean Marett

BioNTech’s chief business and commercial officer Sean Marett will retire on July 1 and will have an advisory role “until the end of the year,” the German drugmaker said in a release. Legal chief James Ryan will assume CBO responsibilities and BioNTech plans to name a new chief commercial officer by the end of the month. Marett was hired as BioNTech’s COO in 2012 after gigs at GSK, Evotec and Next Pharma, and led its commercial efforts as the Pfizer-partnered Comirnaty received the first FDA approval for a Covid-19 vaccine. BioNTech has also built a cancer portfolio that TD Cowen’s Yaron Werber described as “one of the most extensive” in biotech, from antibody-drug conjugates to CAR-T therapies.

Chris Austin

→ GSK has plucked Chris Austin from Flagship and he’ll start his new gig as the pharma giant’s SVP, research technologies on April 1. After a long career at NIH in which he was director of the National Center for Advancing Translational Sciences (NCATS), Austin became CEO of Flagship’s Vesalius Therapeutics, which debuted with a $75 million Series A two years ago this week but made job cuts that affected 43% of its employees six months into the life of the company. In response to Austin’s departure, John Mendlein — who chairs the board at Sail Biomedicines and has board seats at a few other Flagship biotechs — will become chairman and interim CEO at Vesalius “later this month.”

BioMarin has lined up Cristin Hubbard to replace Jeff Ajer as chief commercial officer on May 20. Hubbard worked for new BioMarin chief Alexander Hardy as Genentech’s SVP, global product strategy, immunology, infectious diseases and ophthalmology, and they had been colleagues for years before Hardy was named Genentech CEO in 2019. She shifted to Roche Diagnostics as global head of partnering in 2021 and had been head of global product strategy for Roche’s pharmaceutical division since last May. Sales of the hemophilia A gene therapy Roctavian have fallen well short of expectations, but Hardy insisted in a recent investor call that BioMarin is “still very much at the early stage” in the launch.

Pilar de la Rocha

BeiGene has promoted Pilar de la Rocha to head of Europe, global clinical operations. After 13 years in a variety of roles at Novartis, de la Rocha was named global head of global clinical operations excellence at the Brukinsa maker in the summer of 2022. A short time ago, BeiGene ended its natural killer cell therapy alliance with Shoreline Biosciences, saying that it was “a result of BeiGene’s internal prioritization decisions and does not reflect any deficit in Shoreline’s platform technology.”

Andy Crockett

Andy Crockett has resigned as CEO of KalVista Pharmaceuticals. Crockett had been running the company since its launch in 2011 and will hand the keys to president Ben Palleiko, who joined KalVista in 2016 as CFO. Serious safety issues ended a Phase II study of its hereditary angioedema drug KVD824, but KalVista is mounting a comeback with positive Phase III results for sebetralstat in the same indication and could compete with Takeda’s injectable Firazyr. “If approved, sebetralstat may offer a compelling treatment option for patients and their caregivers given the long-standing preference for an effective and safe oral therapy that provides rapid symptom relief for HAE attacks,” Crockett said last month.

Steven Lo

Vaxart has tapped Steven Lo as its permanent president and CEO, while interim chief Michael Finney will stay on as chairman. Endpoints News last caught up with Lo when he became CEO at Valitor, the UC Berkeley spinout that raised a $28 million Series B round in October 2022. The ex-Zosano Pharma CEO had a handful of roles in his 13 years at Genentech before his appointments as chief commercial officer of Corcept Therapeutics and Puma Biotechnology. Andrei Floroiu resigned as Vaxart’s CEO in mid-January.

Kartik Krishnan

Kartik Krishnan has taken over for Martin Driscoll as CEO of OncoNano Medicine, and Melissa Paoloni has moved up to COO at the cancer biotech located in the Dallas-Fort Worth suburb of Southlake. The execs were colleagues at Arcus Biosciences, Gilead’s TIGIT partner: Krishnan spent two and a half years in the CMO post, while Paoloni was VP of corporate development and external alliances. In 2022, Krishnan took the CMO job at OncoNano and was just promoted to president and head of R&D last November. Paoloni came on board as OncoNano’s SVP, corporate development and strategy not long after Krishnan’s first promotion.

Genesis Research Group, a consultancy specializing in market access, has brought in David Miller as chairman and CEO, replacing co-founder Frank Corvino — who is transitioning to the role of vice chairman and senior advisor. Miller joins the New Jersey-based team with a number of roles under his belt from Biogen (SVP of global market access), Elan (VP of pharmacoeconomics) and GSK (VP of global health outcomes).

Adrian Schreyer

Adrian Schreyer helped build Exscientia’s AI drug discovery platform from the ground up, but he has packed his bags for Nimbus Therapeutics’ AI partner Anagenex. The new chief technology officer joined Exscientia in 2013 as head of molecular informatics and was elevated to technology chief five years later. He then held the role of VP, AI technology until January, a month before Exscientia fired CEO Andrew Hopkins.

Paul O’Neill has been promoted from SVP to EVP, quality & operations, specialty brands at Mallinckrodt. Before his arrival at the Irish pharma in March 2023, O’Neill was executive director of biologics operations in the second half of his 12-year career with Merck driving supply strategy for Keytruda. Mallinckrodt’s specialty brands portfolio includes its controversial Acthar Gel (a treatment for flares in a number of chronic and autoimmune indications) and the hepatorenal syndrome med Terlivaz.

David Ford

→ Staying in Ireland, Prothena has enlisted David Ford as its first chief people officer. Ford worked in human resources at Sanofi from 2002-17 and then led the HR team at Intercept, which was sold to Italian pharma Alfasigma in late September. We recently told you that Daniel Welch, the former InterMune CEO who was a board member at Intercept for six years, will succeed Lars Ekman as Prothena’s chairman.

Ben Stephens

→ Co-founded by Sanofi R&D chief Houman Ashrafian and backed by GSK, Eli Lilly partner Sitryx stapled an additional $39 million to its Series A last fall. It has now welcomed a pair of execs: Ben Stephens (COO) had been finance director for ViaNautis Bio and Rinri Therapeutics, and Gordon Dingwall (head of clinical operations) is a Roche and AstraZeneca vet who led development operations at Mission Therapeutics. Dingwall has also served as a clinical operations leader for Shionogi and Freeline Therapeutics.

Steve Alley

MBrace Therapeutics, an antibody-drug conjugate specialist that nabbed $85 million in Series B financing last November, has named Steve Alley as CSO. Alley spent two decades at Seagen before the $43 billion buyout by Pfizer and was the ADC maker’s executive director, translational sciences.

→ California cancer drug developer Apollomics, which has been mired in Nasdaq compliance problems nearly a year after it joined the public markets through a SPAC merger, has recruited Matthew Plunkett as CFO. Plunkett has held the same title at Nkarta as well as Imago BioSciences — leading the companies to $290 million and $155 million IPOs, respectively — and at Aeovian Pharmaceuticals since March 2022.

Heinrich Haas

→ Co-founded by Oxford professor Adrian Hill — the co-inventor of AstraZeneca’s Covid-19 vaccine — lipid nanoparticle biotech NeoVac has brought in Heinrich Haas as chief technology officer. During his nine years at BioNTech, Haas was VP of RNA formulation and drug delivery.

Kimberly Lee

→ New Jersey-based neuro biotech 4M Therapeutics is making its Peer Review debut by introducing Kimberly Lee as CBO. Lee was hired at Taysha Gene Therapies during its meteoric rise in 2020 and got promoted to chief corporate affairs officer in 2022. Earlier, she led corporate strategy and investor relations efforts for Lexicon Pharmaceuticals.

→ Another Peer Review newcomer, Osmol Therapeutics, has tapped former Exelixis clinical development chief Ron Weitzman as interim CMO. Weitzman only lasted seven months as medical chief of Tango Therapeutics after Marc Rudoltz had a similarly short stay in that position. Osmol is going after chemotherapy-induced peripheral neuropathy and chemotherapy-induced cognitive impairment with its lead asset OSM-0205.

→ Last August, cardiometabolic disease player NeuroBo Pharmaceuticals locked in Hyung Heon Kim as president and CEO. Now, the company is giving Marshall Woodworth the title of CFO and principal financial and accounting officer, after he served in the interim since last October. Before NeuroBo, Woodworth had a string of CFO roles at Nevakar, Braeburn Pharmaceuticals, Aerocrine and Fureix Pharmaceuticals.

Claire Poll

Claire Poll has retired after more than 17 years as Verona Pharma’s general counsel, and the company has appointed Andrew Fisher as her successor. In his own 17-year tenure at United Therapeutics that ended in 2018, Fisher was chief strategy officer and deputy general counsel. The FDA will decide on Verona’s non-cystic fibrosis bronchiectasis candidate ensifentrine by June 26.

Nancy Lurker

Alkermes won its proxy battle with Sarissa Capital Management and is tinkering with its board nearly nine months later. The newest director, Bristol Myers Squibb alum Nancy Lurker, ran EyePoint Pharmaceuticals from 2016-23 and still has a board seat there. For a brief period, Lurker was chief marketing officer for Novartis’ US subsidiary.

→ Chaired by former Celgene business development chief George Golumbeski, Shattuck Labs has expanded its board to nine members by bringing in ex-Seagen CEO Clay Siegall and Tempus CSO Kate Sasser. Siegall holds the top spots at Immunome and chairs the board at Tourmaline Bio, while Sasser came to Tempus from Genmab in 2022.

Scott Myers

→ Ex-AMAG Pharmaceuticals and Rainier Therapeutics chief Scott Myers has been named chairman of the board at Convergent Therapeutics, a radiopharma player that secured a $90 million Series A last May. Former Magenta exec Steve Mahoney replaced Myers as CEO of Viridian Therapeutics a few months ago.

→ Montreal-based Find Therapeutics has elected Tony Johnson to the board of directors. Johnson is in his first year as CEO of Domain Therapeutics. He is also the former chief executive at Goldfinch Bio, the kidney disease biotech that closed its doors last year.

Habib Dable

→ Former Acceleron chief Habib Dable has replaced Kala Bio CEO Mark Iwicki as chairman of the board at Aerovate Therapeutics, which is signing up patients for Phase IIb and Phase III studies of its lead drug AV-101 for pulmonary arterial hypertension. Dable joined Aerovate’s board in July and works part-time as a venture partner for RA Capital Management.

Julie Cherrington

→ In the burgeoning world of ADCs, Elevation Oncology is developing one of its own that targets Claudin 18.2. Its board is now up to eight members with the additions of Julie Cherrington and Mirati CMO Alan Sandler. Cherrington, a venture partner at Brandon Capital Partners, also chairs the boards at Actym Therapeutics and Tolremo Therapeutics. Sandler took the CMO job at Mirati in November 2022 and will stay in that position after Bristol Myers acquired the Krazati maker.

Patty Allen

Lonnie Moulder’s Zenas BioPharma has welcomed Patty Allen to the board of directors. Allen was a key figure in Vividion’s $2 billion sale to Bayer as the San Diego biotech’s CFO, and she’s a board member at Deciphera Pharmaceuticals, SwanBio Therapeutics and Anokion.

→ In January 2023, Y-mAbs Therapeutics cut 35% of its staff to focus on commercialization of Danyelza. This week, the company has reserved a seat on its board of directors for Nektar Therapeutics CMO Mary Tagliaferri. Tagliaferri also sits on the boards of Enzo Biochem and is a former board member of RayzeBio.

→ The ex-Biogen neurodegeneration leader at the center of Aduhelm’s controversial approval is now on the scientific advisory board at Asceneuron, a Swiss-based company focused on Alzheimer’s and Parkinson’s. Samantha Budd-Haeberlein tops the list of new SAB members, which also includes Henrik Zetterberg, Rik Ossenkoppele and Christopher van Dyck.

Read More

Continue Reading

International

Deflationary pressures in China – be careful what you wish for

Until recently, China’s decelerating inflation was welcomed by the West, as it led to lower imported prices and helped reduce inflationary pressures….

Published

on

Until recently, China’s decelerating inflation was welcomed by the West, as it led to lower imported prices and helped reduce inflationary pressures. However, China’s consumer prices fell for the third consecutive month in December 2023, delaying the expected rebound in economic activity following the lifting of COVID-19 controls. For calendar year 2023, CPI growth was negligible, whilst the producer price index declined by 3.0 per cent.

China’s inflation dynamics

China’s inflation dynamics

Chinese consumers are hindered by the weaker residential property market and high youth unemployment. Several property developers have defaulted, collectively wiping out nearly all the U.S.$155 billion worth of U.S. dollar denominated-bonds. 

Meanwhile, the Shanghai Composite Index is at half of its record high, recorded in late 2007. The share prices of major developers, including Evergrande Group, Country Garden Holdings, Sunac China and Shimao Group, have declined by an average of 98 per cent over recent years. Some economists are pointing to the Japanese experience of a debt-deflation cycle in the 1990s, with economic stagnation and elevated debt levels.

Australia has certainly enjoyed the “pull-up effect” from China, particularly with the iron-ore price jumping from around U.S.$20/tonne in 2000 to an average closer to U.S.$120/tonne over the 17 years from 2007. With strong volume increases, the value of Australia’s iron ore exports has jumped 20-fold to around A$12 billion per month, accounting for approximately 35 per cent of Australia’s exports. 

For context, China takes 85 per cent of Australia’s iron ore exports, whilst Australia accounts for 65 per cent of China’s iron ore imports. China’s steel industry depends on its own domestic iron ore mines for 20 per cent of its requirement, however, these are high-cost operations and need high iron ore prices to keep them in business. To reduce its dependence on Australia’s iron ore, China has increased its use of scrap metal and invested large sums of money in Africa, including the Simandou mine in Guinea, which is forecast to export 60 million tonnes of iron ore from 2028.

The Chinese housing market has historically been the source of 40 per cent of China’s steel usage. However, the recent high iron ore prices are attributable to the growth in China’s industrial and infrastructure activity, which has offset the weakness in residential construction.

Whilst this has continued to deliver supernormal profits for Australia’s major iron ore producers (and has greatly assisted the federal budget), watch out for any sustainable downturn in the iron ore price, particularly if the deflationary pressures in China continue into the medium term.

Read More

Continue Reading

International

Deterra Royalties half-yearly result: stable performance and growth Initiatives

Deterra Royalties (ASX:DRR) was established through a strategic demerger from Iluka Resources Ltd (ASX:ILU) in 2020. At the core of Deterra Royalties portfolio…

Published

on

Deterra Royalties (ASX:DRR) was established through a strategic demerger from Iluka Resources Ltd (ASX:ILU) in 2020. At the core of Deterra Royalties portfolio lies long-life, Mining Area C (MAC), a premier iron ore mining operation in the Pilbara region of Western Australia, operationally managed by BHP. This key asset is underpinned by a royalty agreement that ensures Deterra Royalties receives quarterly payments equivalent to 1.232 per cent of the revenue generated, alongside substantial one-off payments of A$1 million for each dry metric tonne increase in annual production capacity. 

South flank, a critical component of the MAC, exemplifies BHP’s latest advancement in iron ore mining, marking its inaugural production in May 2021. In financial year 2023, MAC annual iron ore production amounted to 126 million wet metric tonnes, up 14 per cent on the prior year. The company has reiterated that capacity payments have been set at 118 million tonnes last year and are expected to be updated to current production of 126 million tonnes in June 2024, with potential upside to 145 million tonnes shortly after that. Thus, there is potential upside to dividends of $8 million in capacity payments by June 2024. Meanwhile, revenue amounted to $215.2 million plus a $13 million capacity payment from south flank expansion. Net profit after tax came in at $152.5 million. 

The company distributes 100 per cent of its profits as dividends. 

In a global landscape marked by burgeoning uncertainty and China’s post-COVID-19 economic malaise, Deterra Royalties emerges as providing iron exposure with greater stability. Deterra Royalties offers investors exposure to the iron ore market with distinctly reduced volatility compared to traditional mining entities. 

With that background established, the company released its half-yearly results for FY24, reporting figures that were largely in line with both internal expectations and market consensus. The company continues to explore avenues for portfolio expansion, particularly in bulk, base, and battery commodity royalties, although no deals have been finalised. With substantial undrawn debt facilities of $500 million and recent declines in junior mining company stocks, Deterra Royalties may be moving closer to securing new deals to create new royalties or purchase existing royalties. 

Deterra Royalties reported a net profit after tax (NPAT) of $78.7 million for the first half of FY24, matching internal projections and closely aligning with market estimates, albeit slightly below consensus by three per cent. The declared dividend of $14.89 conditions precedent, representing 100 per cent of NPAT in accordance with Deterra Royalties dividend policy, also fell within anticipated ranges but slightly missed consensus. Revenue for the period stood at A$119 million, consistent with the pre-reported royalty revenue update. 

Operating costs dipped by two per cent from the previous half-year to A$4.3 million but were up by four per cent year-on-year. Notably, business development costs surged to A$1.3 million, marking a 50 per cent increase from the previous period and a 140 per cent rise from the same period last year. This uptick reflects Deterra Royalties intensified efforts to evaluate growth opportunities, as managing director Julian Andrews highlighted. 

Deterra Royalties remains steadfast in its pursuit of growth opportunities, maintaining a flexible approach in both the size and type of investments/royalties sought. The company’s focus spans non-precious metals, including bulk, base, and battery metals, primarily targeting developed mining jurisdictions across Australia, North America, South America, and Europe. Deterra Royalties continues to prioritise royalties for production or near-production companies. 

A company that pays 100 per cent of its earnings as a dividend is relatively easy to value with a discounted cash flow (DCF). Adopting a required return of 6-7 per cent of the weighted average cost of capital (WACC), Deterra Royalties valuation falls in a range between A$4.70 and $5.10 per share. 

In summary, Deterra Royalties’ half-yearly results provided the stable and somewhat predictable operational performance our portfolio managers value, whilst also providing iron ore exposure. 

The Montgomery Fund and the Montgomery [Private] Fund owns shares in Dettera Royalties. This blog was prepared 19 February 2024 with the information we have today, and our view may change. It does not constitute formal advice or professional investment advice. If you wish to trade Deterra Royalties, you should seek financial advice. 

Read More

Continue Reading

Trending